GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

RNST · Mar 31, 2025

RENASANT CORP. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0000715072-25-000180Bank
Sequential deposit growth65thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.deposits

1.37% · CORE · VALID

Net-income growth55thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.net_income

5.35% · CORE · VALID

Interest-income growth50thOwn-history percentile · N=20
Evidence method

Yoy · gp.financial.interest_income

3.35% · CORE · VALID

Cash and equivalents65thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.cash

$1.1B · CORE · VALID

Sequential loan growth45thOwn-history percentile · N=20
Evidence method

Sequential · gp.financial.loans

1.33% · CORE · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History37 statesSelf-history eligible
Period transition

What moved in the state?

Deposit Growth Increased
Previous
0.43%
Current
1.37%
Delta
0.94%
Earnings Growth Decreased
Previous
35.10%
Current
5.35%
Delta
-29.75%
Interest Income Growth Decreased
Previous
11.35%
Current
3.35%
Delta
-7.99%
Liquidity Decreased
Previous
$1.1B
Current
$1.1B
Delta
-$693,000
Loan Growth Decreased
Previous
2.06%
Current
1.33%
Delta
-0.73%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.